Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or...
They have the most developed product in a possible +$6B market. Consider its 80M market cap and think about the possibilities. Revenue is growing and they have money to fund their operations in the future. In MSN Money, you can see that institutions are constantly buying. The 80M Market cap might be problematic and cause price fluctuations soon, but possibly...
All, IF we hold this uptrend at the bottom look like it should break out desc broad wedge pop up hit the speed arc for the biggest gain or wave 4 pullback but more risky there just traidng breakout of red line for decent gain